588 related articles for article (PubMed ID: 15925403)
1. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions.
Lundqvist T
Pharmacol Biochem Behav; 2005 Jun; 81(2):319-30. PubMed ID: 15925403
[TBL] [Abstract][Full Text] [Related]
2. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG
J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological consequences of alcohol and drug abuse on different components of executive functions.
Fernández-Serrano MJ; Pérez-García M; Schmidt Río-Valle J; Verdejo-García A
J Psychopharmacol; 2010 Sep; 24(9):1317-32. PubMed ID: 20007413
[TBL] [Abstract][Full Text] [Related]
4. Real-world memory and executive processes in cannabis users and non-users.
Fisk JE; Montgomery C
J Psychopharmacol; 2008 Sep; 22(7):727-36. PubMed ID: 18208908
[TBL] [Abstract][Full Text] [Related]
5. Executive function deficits in short-term abstinent cannabis users.
McHale S; Hunt N
Hum Psychopharmacol; 2008 Jul; 23(5):409-15. PubMed ID: 18421794
[TBL] [Abstract][Full Text] [Related]
6. Cannabis use, cognitive performance and mood in a sample of workers.
Wadsworth EJ; Moss SC; Simpson SA; Smith AP
J Psychopharmacol; 2006 Jan; 20(1):14-23. PubMed ID: 16204329
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
Curran HV; Brignell C; Fletcher S; Middleton P; Henry J
Psychopharmacology (Berl); 2002 Oct; 164(1):61-70. PubMed ID: 12373420
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
9. Drug-related decrease in neuropsychological functions of abstinent drug users.
van Holst RJ; Schilt T
Curr Drug Abuse Rev; 2011 Mar; 4(1):42-56. PubMed ID: 21466500
[TBL] [Abstract][Full Text] [Related]
10. Attentional control and brain metabolite levels in methamphetamine abusers.
Salo R; Nordahl TE; Natsuaki Y; Leamon MH; Galloway GP; Waters C; Moore CD; Buonocore MH
Biol Psychiatry; 2007 Jun; 61(11):1272-80. PubMed ID: 17097074
[TBL] [Abstract][Full Text] [Related]
11. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
12. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds.
Bedi G; Redman J
Psychol Med; 2008 Sep; 38(9):1319-30. PubMed ID: 18226286
[TBL] [Abstract][Full Text] [Related]
13. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis.
Verdejo-García AJ; López-Torrecillas F; Aguilar de Arcos F; Pérez-García M
Addict Behav; 2005 Jan; 30(1):89-101. PubMed ID: 15561451
[TBL] [Abstract][Full Text] [Related]
15. Cognitive deficits after traumatic coma.
Azouvi P; Vallat-Azouvi C; Belmont A
Prog Brain Res; 2009; 177():89-110. PubMed ID: 19818897
[TBL] [Abstract][Full Text] [Related]
16. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.
Hester R; Lee N; Pennay A; Nielsen S; Ferris J
Exp Clin Psychopharmacol; 2010 Dec; 18(6):489-97. PubMed ID: 21186923
[TBL] [Abstract][Full Text] [Related]
17. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
Reneman L; Schilt T; de Win MM; Booij J; Schmand B; van den Brink W; Bakker O
J Psychopharmacol; 2006 May; 20(3):389-99. PubMed ID: 16574713
[TBL] [Abstract][Full Text] [Related]
18. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
Reay JL; Hamilton C; Kennedy DO; Scholey AB
J Psychopharmacol; 2006 May; 20(3):385-8. PubMed ID: 16574712
[TBL] [Abstract][Full Text] [Related]
19. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?
Fernández-Serrano MJ; Pérez-García M; Verdejo-García A
Neurosci Biobehav Rev; 2011 Jan; 35(3):377-406. PubMed ID: 20451551
[TBL] [Abstract][Full Text] [Related]
20. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
